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Figure 2. Modiﬁed Mankin’s Score.
Figure 3. Number of chondrocytes.
Results: Degeneration of the articular cartilage was observed in the
three areas in both groups, but the change in each area was different.
Histological grading scores in the hyaluronan group were smaller at 12
and 16 weeks compared with that in the saline group (Figure 1, 2). The
thickness of the articular cartilage in the non-contact and contact areas
was unchanged, but it was increased in the transitional area in both
groups. The number of chondrocytes in the contact and transitional areas
was decreased in both groups, but the number in the hyaluronan group
was greater at 12 and 16 weeks compared with that in the saline group
(Figure 3).
Conclusions: HA has chondroprotective effects on the articular cartilage
in a rat immobilized knee model, especially for the number of chondro-
cytes. This result may be due to anti-apoptotic effects of HA on the
articular cartilage.
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Purpose: To investigate the association between inﬂammation and the
incidence and progression of interphalangeal OA and the effect of IFX on
interphalangeal OA.
Methods: Data from patients from the BeSt study with X-rays available
were utilized. In the BeSt study 508 recent-onset rheumatoid arthritis
(RA) patients were randomized into 4 treatment strategies: 1. sequential
monotherapy, 2. step-up combination therapy, 3. combination therapy with
prednisone and 4. IFX and methotrexate (MTX). In groups 1−3, patients
proceeded to treatment with IFX and MTX after failing on at least 3 pre-
vious DMARDs. The IFX dose varied between 3 and 10mg/kg/8 weeks.
X-rays of the hands were scored random in time for osteophytes (grade
0−3 for each joint) using the Osteoarthritis Research Society International
atlas in 10 DIP joints (DIPJs) and 8 PIP joints (PIPJs) at baseline and after
3 years. The incidence and progression of OA was deﬁned as a change
from baseline in the osteophyte score greater than SDC (1.7 units) in
patients without and with one or more osteophytes at baseline. Erosions
were measured according to the Sharp-van der Heijde score.
In multivariate analyses, adjusted for age, gender, postmenopausal status
and BMI, associations between the components of the DAS and erosion
scores and the incidence and progression of interphalangeal OA was
determined.
Results: 416 patients (67% women, mean age 54 years) were included.
At baseline, osteophytes were present in 37% of the patients in one
or more DIPJs and in 13% of the patients in one or more PIPJs. After
3 years, 6 and 4% of the patients had incident OA in the DIPJs and PIPJs.
Radiographic progression was present in 18 and 15% of the patients in
the DIPJs and PIPJs. Number of swollen joints at baseline, erosion score
at baseline, change in erosion score after 3 years and postmenopausal
status were associated with incidence of interphalangeal OA. Change
in erosion scores after 3 years was associated with progression of
interphalangeal OA.
178 (43%) patients were treated with IFX during some period of the study
and these patients had less incident OA (4% in patients who received
IFX versus 7% in patients who did not receive IFX, p = 0.211) and less
progressive OA (10 versus 38%, p = 0.020) in the PIPJs. Combination
therapy with IFX did not affect the incidence of OA (7 versus 7%,
p = 0.974), nor the progression (29 versus 24%, p = 0.516) in the DIPJs.
Conclusions: The incidence and progression of interphalangeal OA was
associated with more inﬂammatory activity in RA patients, suggesting that
inﬂammation might play a role in the pathogenesis of interphalangeal OA.
Combination therapy with inﬂiximab reduced the progression of OA in the
PIPJs in the period of three years after baseline, suggesting that anti-TNF
might be an effective treatment against hand OA.
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Purpose: Clinical reports showed that intra-articular treatment with
Hyaluronic products is safe and effective for treatment of Knee os-
teoarthritis (OA). Similar results appeared in some reports about treat-
ment of hip OA, but data are scarce due to the difﬁculties associated
with the injection technique which requires use of X-ray or ultrasound
(US) guidance. We report from the Italian national database of ANTIAGE
(National Association for Ultrasound Guided Intra-articular Treatment of
Hip) about reduction of NSAID intake after intra-articular injection with
hyaluronic products in patient with hip OA.
Methods: 1887 adults, ambulatory patients with hip OA, selected from
February 2004 to April 2008, underwent to intrarticular injections, per-
formed with US guidance, according to Migliore-Tormenta technique.
Every six months patients were injected with several products, Low and
High MW, like Hylan GF-20 (2ml), Hyalgan (4ml), Hyalubrix, (4ml) and
Jointex (4ml). Monthly NSAID intake, by measuring the number of days
the patient had used NSAID during the previous month, was evaluated
at baseline and every three months. Follow-up period was of 42 months.
A multivariate analysis with Wilcoxon test was performed.
Figure 1. NSAID consumption. p< 0.001 for every value obtained at
follow-up when compared with baseline value.
Results: 1887 patients were injected. We found a statistical reduction
of NSAID already after the ﬁrst injection (p< 0.001), decreasing from
7.37 days per patient at baseline to 3.84 after 6 months from the ﬁrst
injection (Fig. 1). The reduction in NSAID consumption obtained was
